PFIZER INC.

Roche received FDA approval for OCREVUS ZUNOVO™, a subcutaneous injection using Halozyme's ENHANZE® technology for RMS and PPMS, offering a 10-minute, twice-a-year treatment.

Moderna acknowledges slower-than-expected uptake of its RSV vaccine, mResvia, amid competition from GSK and Pfizer. The company adjusts its market expectations and financial guidance, cutting R&D spending and discontinuing several pipeline projects. Moderna plans to focus more on oncology and respiratory disease vaccines, aiming to launch five new products by 2027.

Moderna delays break-even goal to 2028, predicting 2025 sales below current year forecast, due to extended regulatory timelines for flu and cancer vaccines. Shares drop 17.1% to $65.88. Expects $2.5B-$3.5B in 2025 sales, below analyst forecast of $3.74B. Plans to submit FDA applications for RSV and COVID-influenza combo shots.

Valneva SE announces successful pricing of €61,180,000 Private Placement, aiming to fund clinical programs and future growth, including the Shigella vaccine program. The company expects to have sufficient resources until potential milestone and commercial revenues from its Lyme disease program enable sustained profitability.

The 'Clinical Trials: Psychedelic Therapeutics' report reviews global trials, highlighting non-industry sponsors leading (58%), Yale University as top non-industry, Johnson & Johnson as top industry, and CNS as top therapy area (92%). The US leads in trials, and Phase II trials dominate since 2013.

The 'Clinical Trials: Psychedelic Therapeutics' report reviews global trials, highlighting non-industry sponsors leading (58%), with Yale University and Johnson & Johnson as top sponsors. Central nervous system trials dominate (92%), with depression as the top indication. The US leads in North American studies, and Phase II trials have outnumbered others since 2013.

Fulcrum Therapeutics' stock dropped >60% after its Phase 3 REACH trial for losmapimod, a potential FSHD treatment, missed its primary endpoint, leading to the suspension of the program.

Halozyme announces FDA approval for Roche's Tecentriq Hybreza™, a subcutaneous anti-PD-(L)1 immunotherapy using ENHANZE® technology, offering faster administration and broader treatment options for lung, liver, skin, and soft tissue cancers.

The Testicular Cancer Treatment Market is projected to grow at a CAGR of XX% from 2024 to 2031, driven by technological innovations, rising demand, and regulatory changes, reaching $XX billion by 2031. The market is segmented by type and application, with surgical treatments, radiation therapy, chemotherapy, and hormone therapy as key applications.

Moderna delays break-even goal to 2028, expects 2025 sales below 2024 forecast, and plans to cut $1.1 billion in R&D costs from 2026. The company cites challenges in launching new products and slower-than-expected RSV vaccine adoption.